Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Nuance Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Nuance Pharma Announces Partnership With DKSH To Launch Bentrio™ Nasal Spray In Hong Kong And Macau
Details : Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.
Brand Name : Bentrio
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Nuance Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eperisone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Details : Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.
Brand Name : Myonal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : Eperisone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Leo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regiona...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2022
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Leo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The biosimilars planned under this agreement include biosimilar of Prolia® (denosumab, AVT03), Xgeva® (denosumab), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
Brand Name : AVT03
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 07, 2022
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Alvotech and DKSH partner to bring key biosimilar to Asia
Details : Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 24, 2020
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.